(MedPage Today) -- GlaxoSmithKline has withdrawn its U.S. marketing application for a combination of lapatinib (Tykerb) and trastuzumab (Herceptin) for HER2-positive metastatic breast cancer.
via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment